This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Sever, P. Search for Related Content PubMed PubMed Citation Articles by Sever, P. Pubmed/NCBI databases Medline Plus Health Information High Blood Pressure Social Bookmarking                         What's this?

New Hypertension Guidelines from the National Institute for Health and Clinical Excellence and the British Hypertension Society

International Centre for Circulatory Health, Imperial College London, p.sever{at}imperial.ac.uk

A joint initiative between the National Institute for Health and Clinical Excellence (NICE) and the British Hypertension Society (BHS) has led to the publication of new guidelines for the management of hypertension in the community. Recent trial evidence highlighting the increased incidence of new-onset diabetes in those exposed to beta-blocker-based treatment regimens, with or without diuretics, compared with those based on calcium channel blockers (CCBs) or angiotensin-converting enzyme (ACE-Is) inhibitors has led to a recommendation that in the uncomplicated patient, beta-blockers are no longer considered suitable options for first-line therapy. Together with mounting A evidence that age and ethnicity dictate blood pressure (BP) responsiveness to different classes of antihypertensive drugs, the ACD algorithm is now proposed (formerly ABCD), with ACE inhibitors (ACE-Is) (or angiotensin receptor blockers [ARBs] when ACE-Is are poorly tolerated) preferred in younger patients and or patients and CCBs or diuretics preferred for older patientsand in black patients of any age. Pathophysiological considerations have influenced proposals for combination therapies with CCBs or diuretics added to older patients. Health economic analyses have ACE-Is in younger patients and vice versa in clearly indicated the cost effectiveness of CCBs which are now elevated to equal standing with diuretics in older patients.

Key Words: Hypertension • Guidelines • British Hypertension Society • NICE

References

• Kearney PM, Whelton M., Reynolds K., Muntner P., Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005;365:217-23.[Web of Science][Medline] [Order article via Infotrieve]
• Wolf-Maier K., Cooper RS, Kramer H. et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004;43(1):10-17. Epub 2003, Nov 24.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Williams B., Poulter NR, Brown MJ et al. BHS guidelines working party, for the British Hypertension Society. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ 2004;328(7440):634-40.[Free Full Text]
• National Institute for Health and Clinical Excellence (NICE) website - http://www.nice.org.uk/CG034guidance
• European Society of Hypertension-European Society of Cardiology Guidelines Committee 2003. European Society of Hypertension-European Society of Cardiology guidelines for R the management of arterial hypertension. J Hypertens 2003;21(6):1011-53.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Chobanian AV, Bakris GL, Black HR et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC7 Report. Hypertension. 2003;42(6):1206-52. Epub 2003 Dec 1.[Abstract/Free Full Text]
• ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288(23):2981-97.[Abstract/Free Full Text]
• Dahlöf B., Sever PS, Poulter NR, Wedel H., Beevers DG, Caulfield M., Collins R., Kjeldsen SE, Kristinsson A., McInnes GT, Mehlsen J., Nieminen M., O'Brien E., Ostergren J.; for the ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895-906.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Verdecchia P., Reboldi G., Angeli F., et al. Adverse Prognostic significance of new diabetes in treated hypertensive subjects. 2004;43:963-69.
• Julius S., Kjeldsen SE, Weber M., Brunner HR et al. VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363(9426):2022-31.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

Journal of Renin-Angiotensin-Aldosterone System, Vol. 7, No. 2, 61-63 (2006)
DOI: 10.3317/jraas.2006.011


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				L. A. Tomlinson, S. G. Holt, A. R. Leslie, and C. Rajkumar Prevalence of ambulatory hypotension in elderly patients with CKD stages 3 and 4 Nephrol. Dial. Transplant., December 1, 2009; 24(12): 3751 - 3755. [Abstract] [Full Text] [PDF]

				Q. CHE, M. J. SCHREIBER JR, and M. A. RAFEY Beta-blockers for hypertension: Are they going out of style? Cleveland Clinic Journal of Medicine, September 1, 2009; 76(9): 533 - 542. [Abstract] [Full Text] [PDF]

				M. Klapholz {beta}-Blocker Use for the Stages of Heart Failure Mayo Clin. Proc., August 1, 2009; 84(8): 718 - 729. [Abstract] [Full Text] [PDF]

				P. M.W. Bath Antiplatelet Activity Should Be Measured Routinely: No Stroke, June 1, 2009; 40(6): 2273 - 2274. [Full Text] [PDF]

				R. M. Cooper-DeHoff, M. A. Pacanowski, and C. J. Pepine Cardiovascular therapies and associated glucose homeostasis: implications across the dysglycemia continuum. J. Am. Coll. Cardiol., February 3, 2009; 53(5 Suppl): S28 - S34. [Abstract] [Full Text] [PDF]

				R. Dietz, R. Dechend, C.-M. Yu, M. Bheda, J. Ford, M. F. Prescott, and D. L. Keefe Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension1 Journal of Renin-Angiotensin-Aldosterone System, September 1, 2008; 9(3): 163 - 175. [Abstract] [PDF]

This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Sever, P. Search for Related Content PubMed PubMed Citation Articles by Sever, P. Pubmed/NCBI databases Medline Plus Health Information High Blood Pressure Social Bookmarking                         What's this?